Author Archives: Janet Stewart, MSc

Roche Licenses Promising Huntington’s Therapy IONIS-HTTRx, Begins Extension Study

Roche will now be responsible for the development and marketing of Ionis Pharmaceuticals’ IONIS-HTTRx after exercising its option to license the investigational drug, designed to treat Huntington’s disease (HD). This move follows highly promising results from a Phase 1/2a clinical trial. The randomized, double-blind, placebo-controlled trial (NCT02519036) tested…